KYTX Stock Forecast & Price Target

Kyverna Therapeutics is viewed positively because its lead CD19 CAR-T, KYV-101, is showing broad autoimmune proof-of-concept across difficult-to-treat diseases, with all six ACPA-positive, treatment-refractory RA patients improving after one infusion and 66.6% reaching ACR70 by Week 36, alongside durable biomarker reductions and no high-grade CRS or ICANS. The commercial case is strengthened by stiff person syndrome, where KYSA-8 delivered a 46% median Timed 25-Foot Walk improvement at Week 16, 81% of patients hit a clinically meaningful threshold, 100% stayed off immunotherapies, and management now expects a 2027 launch with about $800M in peak sales potential. Financially, the company’s $279M cash position supports runway into 2028, while dual-source U.S. manufacturing, >98% manufacturing success, and a path to biologics-like margins support execution of the first autoimmune CAR-T franchise.

Kyverna Therapeutics is a clinical-stage, pre-revenue biopharmaceutical company whose valuation remains highly dependent on uncertain clinical outcomes for KYV-101 and KYV-201, with only low probabilities of approval assigned to LN and MG and, in one framework, 70% for SPS. The company’s DCF assumptions rely on end-2026 or end-2Q27 cash positions and enterprise values of about $1.4B to ~$2B, but these estimates are fragile because they exclude other indications and hinge on unproven durability of responses. The negative outlook is driven by the risk that current data in LN, MG, and SPS fail to mature into durable efficacy or approval, alongside long-term dilution risk that could pressure shareholders.